Abstract
Nanotechnology is a rapidly emerging drug-delivery system that makes possible the controlled release of small molecules, and nanodelivery of therapeutic molecules using nanoparticles or nanogels represents a major improvement for more focused delivery of such therapeutic molecules. The delivery of insulin for the control of diabetes mellitus (DM) and aldose reductase inhibitor (ARI) for diabetic complications may provide better treatment of diabetes. A structural overview of aldose reductase including computational docking experiments with HAR-1, various ARIs, aldose-keto reductase, and nanodelivery of insulin, ARI's, and drug molecules are described.
Keywords: Aldose reductase, aldose reductase inhibitors, aldo-keto reductase, diabetes, insulin, nanodelivery, nanogels, tricyclic pyrone molecules, sorbitol, dehydrogenase, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, glutathione reductase, glycation, nasal, rectal, pulmonary, microparticles, pre-clinical
Mini-Reviews in Medicinal Chemistry
Title:Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Volume: 12 Issue: 4
Author(s): A. M. Prior, M. Thapa, D. H. Hua
Affiliation:
Keywords: Aldose reductase, aldose reductase inhibitors, aldo-keto reductase, diabetes, insulin, nanodelivery, nanogels, tricyclic pyrone molecules, sorbitol, dehydrogenase, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, glutathione reductase, glycation, nasal, rectal, pulmonary, microparticles, pre-clinical
Abstract: Nanotechnology is a rapidly emerging drug-delivery system that makes possible the controlled release of small molecules, and nanodelivery of therapeutic molecules using nanoparticles or nanogels represents a major improvement for more focused delivery of such therapeutic molecules. The delivery of insulin for the control of diabetes mellitus (DM) and aldose reductase inhibitor (ARI) for diabetic complications may provide better treatment of diabetes. A structural overview of aldose reductase including computational docking experiments with HAR-1, various ARIs, aldose-keto reductase, and nanodelivery of insulin, ARI's, and drug molecules are described.
Export Options
About this article
Cite this article as:
A. M. Prior, M. Thapa, D. H. Hua , Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics, Mini-Reviews in Medicinal Chemistry 2012; 12 (4) . https://dx.doi.org/10.2174/138955712799829294
DOI https://dx.doi.org/10.2174/138955712799829294 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antidiabetic Medicinal Plants as a Source of Alpha Glucosidase Inhibitors
Current Diabetes Reviews Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes
Current Diabetes Reviews Recent Advances and Patents for Nerve Scaffold Biomaterials and their Use for Local, Non-Viral Delivery of Growth Factors and Nucleic Acids
Recent Patents on Biomedical Engineering (Discontinued) Symptomatic Improvement, Increased Life-Span and Sustained Cell Homing in Amyotrophic Lateral Sclerosis After Transplantation of Human Umbilical Cord Blood Cells Genetically Modified with Adeno-Viral Vectors Expressing a Neuro-Protective Factor and a Neural Cell Adhesion Molecule
Current Gene Therapy Gene Therapy for Neuroprotection and Neurorestoration (Part I)
Current Gene Therapy Novel Approaches for Potential Therapy of Cystic Fibrosis
Current Drug Targets Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Combination of Naringenin and Lisinopril Ameliorates Nephropathy in Type-1 Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Candidate Genes Implicated in Type 1 Diabetes Susceptibility
Current Diabetes Reviews Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis
Current Neuropharmacology EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle
Current Genomics Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Disentangling the Role of the Tau Gene Locus in Sporadic Tauopathies
Current Alzheimer Research Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design